Literature DB >> 9168445

In vitro culture studies of childhood myelodysplastic syndrome: establishment of the cell line MUTZ-1.

K G Steube1, S M Gignac, Z B Hu, D Teepe, D Harms, H Kabisch, G Gaedicke, T Hansen-Hagge, R A Macleod, H Quentmeier, H G Drexler.   

Abstract

Myelodysplastic syndrome (MDS) in childhood is considered to be very rare and detailed pathobiological data are scarce. More biological information regarding MDS in children is clearly needed and in vitro culture studies provide one possibility for gaining further pathophysiological insights into this malignancy. Here, we incubated bone marrow samples from 30 children with MDS in liquid suspension culture in order to grow the transformed cells in vitro. In most cultures, the hematopoietic cells died quickly and only fibroblastic (stromal) background layers proliferated temporarily; several normal Epstein-Barr virus (EBV)-transformed B-lymphoblastoid cell lines (B-LCL) were established. Only in one instance, albeit from the peripheral blood and not from the bone marrow, could we establish a cell line, termed MUTZ-1, from the malignant cells of a 5-year-old girl with MDS (FAB subtype refractory anemia with excess of blasts). The MDS arose from a pre-existing Fanconi anemia and progressed quickly to an acute myeloid leukemia (FAB M2). Despite positivity for EBV, MUTZ-1 is not an EBV + B-LCL and further characterization of MUTZ-1 confirmed the derivation from the transformed clonal cells. Immunophenotyping showed a pre B-cell surface marker profile (CD10+ CD19+ cytoplasmic IgM+); receptor gene rearrangement analyses underlined the clonal B-cell nature of MUTZ-1 cells. MUTZ-1 cells exhibit a highly rearranged, unstable karyotype with a high frequency of spontaneous chromatid breaks and exchanges; del(5q) and additional rearrangements involving chromosome 5 [der(15)t(5;15)] were detected. The present data and results from a few other MDS-derived cell lines suggest that the transforming event in MDS seems to occur in an immature pluripotent progenitor cell. The new MDS-derived continuous cell line MUTZ-1 provides a useful in vitro model system for studies on the pathogenetic events leading to MDS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9168445     DOI: 10.3109/10428199709114174

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  11 in total

1.  Chidamide shows synergistic cytotoxicity with cytarabine via inducing G0/G1 arrest and apoptosis in myelodysplastic syndromes.

Authors:  Zhaoyun Liu; Jin Chen; Honglei Wang; Kai Ding; Yanqi Li; Anya de Silva; Varun Sehgal; Jonathan Lvan Burbano; Radhika Sundararaj; Janani Gamage; Victor Audu; Rong Fu
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

Review 2.  Mouse models of myelodysplastic syndromes.

Authors:  Sarah H Beachy; Peter D Aplan
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

3.  Antitumor activity and drug interactions of proteasome inhibitor Bortezomib in human high-risk myelodysplastic syndrome cells.

Authors:  Jian Huang; Ting Ding; Min Yang; Hui Liu; Xin Sun; Jie Jin
Journal:  Int J Hematol       Date:  2011-03-31       Impact factor: 2.490

Review 4.  A research review of experimental animal models with myelodysplastic syndrome.

Authors:  Gen-Wang Chen; Mei-Na Chen; Lei Liu; Yu-Yu Zheng; Jin-Peng Wang; Si-Si Gong; Rong-Fu Huang; Chun-Mei Fan; Yue-Zu Chen
Journal:  Clin Transl Oncol       Date:  2022-09-06       Impact factor: 3.340

5.  NUP98-HOX translocations lead to myelodysplastic syndrome in mice and men.

Authors:  Christopher Slape; Ying Wei Lin; Helge Hartung; Zhenhua Zhang; Linda Wolff; Peter D Aplan
Journal:  J Natl Cancer Inst Monogr       Date:  2008

6.  Targeting the Sonic Hedgehog-Gli1 Pathway as a Potential New Therapeutic Strategy for Myelodysplastic Syndromes.

Authors:  Jixue Zou; Zhigang Zhou; Liping Wan; Yin Tong; Youwen Qin; Chun Wang; Kun Zhou
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

7.  Reversal of bortezomib resistance in myelodysplastic syndrome cells by MAPK inhibitors.

Authors:  Yingxing Yue; Ying Wang; Yang He; Shuting Yang; Zixing Chen; Yuanyuan Wang; Shanshan Xing; Congcong Shen; Hesham M Amin; Depei Wu; Yao-Hua Song
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

8.  Sonic hedgehog produced by bone marrow-derived mesenchymal stromal cells supports cell survival in myelodysplastic syndrome.

Authors:  Jixue Zou; Yan Hong; Yin Tong; Ju Wei; Youwen Qin; Shan Shao; Chun Wang; Kun Zhou
Journal:  Stem Cells Int       Date:  2015-03-15       Impact factor: 5.443

9.  Downregulation of hTERT: an important As2O3 induced mechanism of apoptosis in myelodysplastic syndrome.

Authors:  Weilai Xu; Yungui Wang; Hongyan Tong; Wenbin Qian; Jie Jin
Journal:  PLoS One       Date:  2014-11-21       Impact factor: 3.240

10.  Abnormal Ferroptosis in Myelodysplastic Syndrome.

Authors:  Qi Lv; Haiyue Niu; Lanzhu Yue; Jiaxi Liu; Liyan Yang; Chunyan Liu; Huijuan Jiang; Shuwen Dong; Zonghong Shao; Limin Xing; Huaquan Wang
Journal:  Front Oncol       Date:  2020-09-02       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.